Pathology
PMCID: PMC12180351 PMID: 40531801 DOI: 10.1080/07853890.2025.2520401 Journal: Annals of medicine Publication Date: 2025-6-18 Authors: Mai W, Fan X, Zhang L, Li J, Chen L, et al. Key Points * 2.5D deep learning approach significantly improves diagnostic accuracy of parotid gland tumors * Model achieved AUC of 0.
Infectious_Disease
PMCID: PMC12176103 PMID: 40531798 DOI: 10.15585/mmwr.mm7422a3 Journal: MMWR. Morbidity and mortality weekly report Publication Date: 2025-6-19 Authors: Rao AK, Minhaj FS, Carter RJ, Duffy J, Satheshkumar PS, et al. Key Points * JYNNEOS is safe and recommended for diverse populations, including those with atopic dermatitis, immunocompromising conditions, and
Pharmacology
PMCID: PMC12171949 PMID: 40525269 DOI: 10.1111/myc.70076 Journal: Mycoses Publication Date: 2025-6-17 Authors: Parsay S, Saeedi M, Abastabar M, Hedayati MT, Rahimnia SM, et al. Key Points * Nanostructured lipid carriers enabled a more targeted and efficient delivery of terbinafine for onychomycosis treatment * Clinical severity index reduction of 45%
Oncology
PMCID: PMC12175362 PMID: 40533767 DOI: 10.1186/s13046-025-03436-1 Journal: Journal of experimental & clinical cancer research : CR Publication Date: 2025-6-18 Authors: Wan W, Li Y, Sun W, Cheng Z, Ma F, et al. Key Points * Anti-DCDC2 autoantibodies emerge as a potential novel diagnostic biomarker for intrahepatic cholangiocarcinoma * DCDC2 promotes ICC
Obstetrics_Gynecology
PMCID: PMC12176146 PMID: 40531933 DOI: 10.1371/journal.pone.0325906 Journal: PloS one Publication Date: 2025-6-18 Authors: Hertting E, Herling L, Lindqvist PG, Wiberg-Itzel E Key Points * Antenatal identification of early-onset FGR reduces stillbirth risk but increases risks of severe newborn and childhood outcomes * Early-onset FGR identification associated with 81%
Oncology
PMCID: PMC12173198 PMID: 40526100 DOI: 10.18632/oncotarget.28742 Journal: Oncotarget Publication Date: 2025 Authors: Fei F, Telatar M, Tomasian V, Chang L, Danilova O, et al. Key Points * TET2 and ASXL1 mutations were predominant, occurring in 57% and 33% of BPDCN cases, respectively * Patients with ≥3 mutations and TET2
Oncology
PMCID: PMC12176387 PMID: 40530955 DOI: 10.7554/eLife.99849 Journal: eLife Publication Date: 2025-6-18 Authors: Li K, Liang J, Li N, Fang J, Zhou X, et al. Key Points * NPC-RSS provides a robust, data-driven approach to predicting radiotherapy response in nasopharyngeal carcinoma * Model achieved high predictive accuracy with AUC of
Pathology
PMCID: PMC12177075 PMID: 40533487 DOI: 10.1038/s42003-025-08317-z Journal: Communications biology Publication Date: 2025-6-18 Authors: Yamauchi K, Koike M, Hioki H Key Points * Nanobody-based 3D-IHC technique provides superior tissue penetration compared to conventional antibodies * Achieved 9.0-fold signal amplification compared to standard fluorescence imaging * Enables multiplex molecular imaging in thick
Oncology
PMCID: PMC12174473 PMID: 40528483 DOI: 10.1002/cnr2.70218 Journal: Cancer reports (Hoboken, N.J.) Publication Date: 2025-6-17 Authors: Ran R, Wang M, Miao J Key Points * Identified 11 key genes (including POU4F3, MAL, MAGI2) that play critical roles in endometrial cancer progression through epigenetic dysregulation * Recurrence model AUC values:
Immunology
PMCID: PMC12173411 PMID: 40526725 DOI: 10.1371/journal.ppat.1013228 Journal: PLoS pathogens Publication Date: 2025-6-17 Authors: Zhou J, Yang Q, Xu H, Chen H, Jiang N, et al. Key Points * TIGIT expression on CD8+ T cells is significantly elevated in active TB patients and correlates with disease severity * TIGIT
Immunology
PMCID: PMC12178997 PMID: 40536609 DOI: 10.1007/s12032-025-02822-1 Journal: Medical oncology (Northwood, London, England) Publication Date: 2025-6-19 Authors: Zamani MR, Šácha P Key Points * Non-antibody immune checkpoint inhibitors represent a promising frontier in cancer immunotherapy, offering more targeted and potentially less toxic treatment approaches * Multiple novel ICI candidates are currently
Pathology
PMCID: PMC12175355 PMID: 40533866 DOI: 10.1186/s41065-025-00476-7 Journal: Hereditas Publication Date: 2025-6-18 Authors: Wen X, Zhu J, Xi D, Chen M, Zeng D, et al. Key Points * EZF expression is significantly downregulated in lung adenocarcinoma, yet correlates with advanced tumor progression * High-risk patients with low EZF expression showed 1.